scholarly journals Low Free Testosterone Levels Are Associated With All-Cause and Cardiovascular Mortality in Postmenopausal Diabetic Women

Diabetes Care ◽  
2011 ◽  
Vol 34 (8) ◽  
pp. 1771-1777 ◽  
Author(s):  
Elisabeth Wehr ◽  
Stefan Pilz ◽  
Bernhard O. Boehm ◽  
Tanja B. Grammer ◽  
Winfried März ◽  
...  
Keyword(s):  
Cardiovascular Mortality ◽  
Free Testosterone ◽  
Testosterone Levels

Free Testosterone Level And Quality of Cauda Epididymis Sperm of Local Rabbit That Given Commercial Feed Supplemented By Cod Fish Liver Oil

2016 ◽  
Vol 2 (3) ◽  
pp. 1
Author(s):  
Ni Gusti Ayu Manik Ermayanti ◽  
I Gusti Lanang Oka ◽  
I Gede Mahardika ◽  
I Putu Suyadnya
Keyword(s):  
Testosterone Level ◽  
Sperm Quality ◽  
Free Testosterone ◽  
Fish Liver ◽  
Testosterone Levels ◽  
Commercial Feed ◽  
One Way Anova ◽  
Free Testosterone Level ◽  
Range Test

This study was intended to determine the free testosterone levels and sperm quality of local rabbit that was given commercial feed supplemented cod fish liver oil.  The experiment design that was used in this research was Complete Random Design (CRD) with four experiments of feed, i.e. commercial feed without cod fish liver oil (R-0) as control, commercial feed + 1,5% cod fish liver oil (R-1), commercial feed + cod fish liver oil 3% (R-2), commercial feed + cod fish liver oil 4,5% (R-3). The each experiment included eight rabbits and feed experiment was given starting by 13 weeks to 26 weeks years old. The variable that observed was free testosterone level and sperm quality of local rabbit. The data that was obtained to be analyzed with One Way Anova and if its contrast was done more test with Duncan’s Multiple Range Test (DMRT). The result of this research was to show that supplementation of cod fish liver oil in commercial feed was to show the result that a real distinction of (P<0, 05) towards free testosterone level and sperm quality of local rabbit.

Increased Free Testosterone Levels in Men with Uncontrolled Type 2 Diabetes Five Years After Randomization to Bariatric Surgery

2017 ◽  
Vol 28 (1) ◽  
pp. 277-280 ◽  
Author(s):  
Nathan H. Pham ◽  
James Bena ◽  
Deepak L. Bhatt ◽  
Laurence Kennedy ◽  
Philip R. Schauer ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Bariatric Surgery ◽  
Free Testosterone ◽  
Testosterone Levels

scholarly journals LONGITUDINAL CHANGES OF FREE TESTOSTERONE LEVELS AND SEXUAL FUNCTION IN JAPANESE MEN EVALUATING TWO CROSS-SECTIONAL COMMUNITY-BASED STUDIES

2018 ◽  
Vol 109 (1) ◽  
pp. 20-24 ◽  
Author(s):  
Akio Takayanagi ◽  
Ko Kobayashi ◽  
Fumimasa Fukuta ◽  
Hidetoshi Tabata ◽  
Masahiro Matsuki ◽  
...  
Keyword(s):  
Sexual Function ◽  
Free Testosterone ◽  
Community Based ◽  
Cross Sectional ◽  
Japanese Men ◽  
Longitudinal Changes ◽  
Testosterone Levels

Hormonal impact of salvage chemotherapy with carboplatin plus weekly docetaxel in patients with castration- and docetaxel-resistant prostate cancer (DRPC).

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 74-74
Author(s):  
Christoph W. Reuter ◽  
Michael A. Morgan ◽  
Martin Fenner ◽  
Viktor Grünwald ◽  
Arnold Ganser
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Progression Free Survival ◽  
Free Testosterone ◽  
Salvage Chemotherapy ◽  
Testosterone Levels ◽  
Chain Cleavage ◽  
Cleavage Enzyme ◽  
Testosterone Biosynthesis ◽  
Grade 3

74 Background: Recent data suggest that carboplatin may be effective in combination with docetaxel in DRPC. Platinum(II)-complexes have been shown to interfere with testosterone biosynthesis by inhibiting the cholesterol side chain cleavage enzyme (CYP11A1), 3b-hydroxysteroid dehydrogenase (HSD3B1,2) and 17a hydroxylase/C17,20-lyase (CYP17A1). Methods: Docetaxel failure/resistance was defined according to the Prostate Cancer Working Group (PCWG2 2007) criteria. Since February 2005, 68 consecutive DRPC pts were treated with at least two cycles of carboplatin AUC5 iv for 30 min on day 1 every 4 weeks (q4w), docetaxel at a dose of 35 mg/m2 iv for one hour on days 1, 8, (15) plus prednisone 2x5mg/day orally after receiving informed consent until disease progression or occurrence of intolerable adverse effects. Efficacy measures were done following PCWG2 recommendations. Free testosterone levels were measured before (n=42) and during DC treatment (n=36). Results: Response of prostate-specific antigen (PSAR; ≥50% PSA) was observed in 32/68 (47.1%) patients. At the time of the current analysis the median follow-up time was 13.6 months and 43/68 patients had died. Median progression-free survival (PFS) for all patients was 7.5 months (CI 95% 5.4, 9.5) and median overall survival (OS) was 18.6 months (CI 95% 12.3, 24.9). In PSAR, PFS was 15.7 versus 4.8 months in PSANR (p<0.001; hazard ratio HR 0.19, CI 0.09, 0.39) and OS was 25.6 versus 8.1 months (p<0.001; HR 0.21 CI 0.10, 0.42). This regimen was reasonably well tolerated, with leukopenia/neutropenia as the most common reversible grade 3/4 toxicity (39.7/33.8%). Median free testosterone levels were 0.935 pg/ml before and 0.185 pg/ml during DC treatment (nadir; p<0.001). While free testosterone levels before DC treatment were associated with lower PSAR (HR 6.32 CI 1.60, 25,0; p=0.009), free testosterone nadir levels <0.18 pg/ml during DC treatment were associated with higher PFS (HR 0.126 CI 0.04, 0.46, p=0.002) and OS (HR 0.07 CI 0.008, 0.53; p=0.01). Conclusions: These data suggest that DC may be an important second-line treatment option for DRPC patients by inhibiting the testosterone biosynthesis.

Sign in / Sign up

Export Citation Format

Share Document